Cargando…

Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study

OBJECTIVES: Lipid abnormalities associated with antiretroviral therapy in people with HIV infection are more frequent with protease inhibitors (PI)-based regimens. Whether effects extend to patients receiving a PI subsequent to failure on non-nucleoside reverse-transcriptase inhibitors (NNRTI)-based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pefura Yone, Eric Walter, Kengne, André Pascal, Ashuntantang, Gloria, Betyoumin, Awa Foueudjeu, Ngogang, Jeanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2012
Materias:	Infectious Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425906/ https://www.ncbi.nlm.nih.gov/pubmed/22874631 http://dx.doi.org/10.1136/bmjopen-2012-001317

Ejemplares similares

First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study
por: Pefura Yone, Eric Walter, et al.
Publicado: (2011)

Incidence, time and determinants of tuberculosis treatment default in Yaounde, Cameroon: a retrospective hospital register-based cohort study
por: Pefura Yone, Eric Walter, et al.
Publicado: (2011)

Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2022)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors
por: Yang, Yang, et al.
Publicado: (2018)

Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013)

Coagulation Inhibitors in COVID-19 Leading to Compressive Airway Hematoma
por: Mohamed, Amr
Publicado: (2021)

Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060
por: Hobbs, Charlotte V., et al.
Publicado: (2016)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Cryptococcal Pneumonia in a Patient on Tyrosine Kinase Inhibitor Therapy: How Common Is It?
por: Sung, Deny, et al.
Publicado: (2023)

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors
por: Yin, Dwight E., et al.
Publicado: (2020)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency
por: Aoki, Manabu, et al.
Publicado: (2017)

Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
por: Solaimanzadeh, Isaac
Publicado: (2020)

Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
por: Jochmans, Dirk, et al.
Publicado: (2010)

What is the association of renin–angiotensin–aldosterone system inhibitors with COVID-19 outcomes: retrospective study of racially diverse patients?
por: Khodneva, Yulia, et al.
Publicado: (2022)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Population-based cohort study on the risk of pneumonia in patients with non-traumatic intracranial haemorrhage who use proton pump inhibitors
por: Ho, Sai-Wai, et al.
Publicado: (2014)

Prevalence and risk factors of chronic kidney disease in urban adult Cameroonians according to three common estimators of the glomerular filtration rate: a cross-sectional study
por: Kaze, Francois Folefack, et al.
Publicado: (2015)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2020)

Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy
por: Shiiba, Ritsuya, et al.
Publicado: (2022)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Non-conversion of sputum culture among patients with smear positive pulmonary tuberculosis in Cameroon: a prospective cohort study
por: Pefura-Yone, Eric Walter, et al.
Publicado: (2014)

Sensitisation to mites in a group of patients with asthma in Yaounde, Cameroon: a cross-sectional study
por: Pefura-Yone, Eric Walter, et al.
Publicado: (2014)

HIV testing, HIV status and outcomes of treatment for tuberculosis in a major diagnosis and treatment centre in Yaounde, Cameroon: a retrospective cohort study
por: Yone, Eric Walter Pefura, et al.
Publicado: (2012)

Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin
por: Muirhead, Corinne, et al.
Publicado: (2017)

Outcome measurement of extensive implementation of antimicrobial stewardship in patients receiving intravenous antibiotics in a Japanese university hospital
por: Niwa, T, et al.
Publicado: (2012)

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
por: Chang, Hui-Min, et al.
Publicado: (2021)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_06ulkemmf2p441j88tvv83vebk